









Markets
/
Stocks
/
nasdaq-celu
/

Celularity Inc

CELU

1.300USD

+0.130+11.11%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

36.68MMarket Cap

LossP/E TTM



Celularity Inc

1.300

+0.130+11.11%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Celularity Inc

Currency: USD Updated: 2026-02-06

Key Insights

Celularity Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 109 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Celularity Inc's Score

Industry at a Glance

Industry Ranking

109 / 159

Overall Ranking

316 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Celularity Inc Highlights

StrengthsRisks

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 201.64% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 54.22M.

Fairly Valued

The company’s latest PE is -0.39, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 42.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.90.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+412.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Celularity Inc is 6.78, ranking 139 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 5.28M, representing a year-over-year decrease of 43.16%, while its net profit experienced a year-over-year decrease of 43.35%.

Score

Industry at a Glance

Previous score

6.78

Change



Financials

4.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.22

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Celularity Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Celularity Inc is 8.58, ranking 13 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.39, which is -3001.66% below the recent high of 11.34 and -711.49% above the recent low of -3.17.

Score

Industry at a Glance

Previous score

8.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Celularity Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+412.82%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Celularity Inc

CELU

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Celularity Inc is 3.35, ranking 151 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.39 and the support level at 1.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.95

Change

0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.018

Neutral

RSI(14)

50.008

Neutral

STOCH(KDJ)(9,3,3)

51.493

Buy

ATR(14)

0.080

Low Volatility

CCI(14)

40.408

Neutral

Williams %R

35.000

Buy

TRIX(12,20)

-0.400

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.232

Buy

MA10

1.248

Buy

MA20

1.276

Buy

MA50

1.438

Sell

MA100

1.701

Sell

MA200

2.075

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Celularity Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 13.73%, representing a quarter-over-quarter decrease of 16.12%. The largest institutional shareholder is The Vanguard, holding a total of 676.65K shares, representing 2.35% of shares outstanding, with 5.48% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Genting Bhd

6.34M

Hariri (Robert J)

2.86M

+0.11%

Starr International Company, Inc.

1.53M

Lincoln Alternative Strategies LLC

1.23M

C.V. Starr & Co., Inc.

764.07K

The Vanguard Group, Inc.

Star Investors

676.65K

+35.29%

Ling (Geoffrey M. D.)

472.29K

+68.75%

Diamandis (Peter)

441.18K

+77.35%

Parks (Diane L.)

344.98K

+126.12%

Levien (Vincent)

128.70K

+3379.29%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Celularity Inc is 2.09, ranking 138 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.